Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TURF: Aflibercept for Recalcitrant Wet AMD
NCT01543568Phase 4Completed
- Sponsor
- David M. Brown
- Start
- Feb 2012
- Primary completion
- Oct 2014
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aflibercept in exudative age-related macular degeneration, sponsored by David M. Brown. Primary endpoint: The Number of Patients With no Fluid on OCT at 6 months. Started Feb 2012; status: completed.
02
Drugs
aflibercept
03
Conditions
exudative age-related macular degeneration
Beyond the preview
Go deeper on NCT01543568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01543568.